Sanofi signs Iran deal; India's Wockhardt has more FDA issues;

@FiercePharma: Gilead's John Martin replacing Milligan as CEO. Release | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Novartis is revamping its manufacturing after having disposed of 25 plants. Story | Follow @EricPFierce

@CarlyHFierce: Riding Q4 diabetes growth, Lilly aims for even more with Jardiance. Report | Follow @CarlyHFierce

> Presidential candidate Hillary Clinton continues to demonize Valeant Pharmaceuticals ($VRX) and its drug price hikes, with her campaign posting a video of her in Iowa calling the increases, "predatory" and wrong. Story

> India's Wockhardt has reportedly received an FDA Form 483 for another of its plants. Story

> Sanofi ($SNY) says it has has signed a memorandum of cooperation with Iran in which it will consider expanding partnerships with local manufacturers and transfer technology to Iran. Report

Medical Device News

@FierceMedDev: ICYMI: Investor urges J&J to spin out poor-performing device, consumer businesses. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Sony, Carlyle Group, KKR among bidders for Toshiba's imaging unit, expected to fetch $3B+. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: J&J to fork over $120M to settle thousands of vaginal mesh suits. Article | Follow @EmilyWFierce

> Vascular Flow Technologies raises $14M+ for its prosthetic vascular graft. Story

> Walgreens severs some ties to Theranos amid CMS lab inspection fallout. Report

Biotech News

@FierceBiotech: ICYMI: Merck gets FDA OK to go toe-to-toe with Gilead's hep C market goliath. Article | Follow @FierceBiotech

@JohnCFierce: Gee, so Allergan does R&D? How surprising. (droll overtone here.) rapastinel/GLYX-13 BTD $AGN. Release | Follow @JohnCFierce

@DamianFierce: this man missed a huge opportunity in orthopedics. More from STAT | Follow @DamianFierce

> Allergan's depression drug bags a 'breakthrough' tag on the way to Phase III. Article

> Replacing a biotech legend, Gilead's new CEO inherits sky-high expectations. Story

> Allergan links with AstraZeneca on new antibiotic treatment. Report

Suggested Articles

After early threats, the FDA finished reviewing the company's response to a citation for data manipulation and decided not to take any further action.

China is quickly getting back up to speed with API production but reports freight bottlenecks are slowing deliveries.

Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.